Immunization of Mice with a DNA Vaccine Based on Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fragment 1

Zhao, Bo; Jin, Ningyi; Zhang, Li-Shu; Zhang, Yingjiu

doi:10.1089/vim.2006.19.518

Cited by 7 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently reported SARS vaccines are based on the full-length or fragments of SARS-CoV S protein (20,25,26). They can effectively induce NA, cellular, and/or protective immune responses against SARS-CoV (16,17,22).…”

Section: Intranasal Vaccination Of Recombinant Adeno-associated Virusmentioning

confidence: 99%

Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection

Zhao

Lin

et al. 2008

The Journal of Immunology

131

138

View full text Add to dashboard Cite

We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-γ-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and less pulmonary pathological damage, while no Ab-mediated disease enhancement effect was observed; and 5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.

show abstract

Section: Intranasal Vaccination Of Recombinant Adeno-associated Virusmentioning

confidence: 99%

Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection

Zhao

Lin

et al. 2008

The Journal of Immunology

131

138

View full text Add to dashboard Cite

show abstract

“…A DNA vaccine encoding the S protein induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial (Martin et al, 2008). Since the full-length S protein-based vaccines might induce potential harmful immune responses (Czub et al, 2005; Weingartl et al, 2004), vaccines based on the fragments of S protein, such as RBD, have a greater potential for developing into effective vaccines against SARS (Lee et al, 2006; Zhao et al, 2006; Zhou et al, 2006). …”

Section: Introductionmentioning

confidence: 99%

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity

et al. 2009

View full text Add to dashboard Cite

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease. The potential recurrence of the disease from animal reservoirs highlights the significance of development of safe and efficient vaccines to prevent a future SARS epidemic. In this study, we expressed the recombinant receptor-binding domain (rRBD) in mammalian (293T) cells, insect (Sf9) cells, and E. coli, respectively, and compared their immunogenicity and protection against SARS-CoV infection in an established mouse model. Our results show that all rRBD proteins expressed in the above systems maintained intact conformation, being able to induce highly potent neutralizing antibody responses and complete protective immunity against SARS-CoV challenge in mice, albeit the rRBD expressed in 293T cells elicited stronger humoral immune responses with significantly higher neutralizing activity (P < 0.05) than those expressed in Sf9 and E. coli cells. These results suggest that all three rRBDs are effective in eliciting immune responses and protection against SARS-CoV and any of the above expression systems can be used for production of rRBD-based SARS subunit vaccines. Preference will be given to rRBD expressed in mammalian cells for future evaluation of the vaccine efficacy in a non-human primate model of SARS because of its ability to refold into a native conformation more readily and to induce higher level of neutralizing antibody responses than those expressed in E. coli and insect cells.

show abstract

“…It is revealed that a DNA vaccine encoding SARS-CoV S protein induces neutralizing antibody as well as T cell responses that protect vaccinated mice from SARS-CoV challenge [73]. In addition, IgG antibody and T cell-mediated immune responses are induced by DNA vaccines encoding S1 of SARS-CoV [74]. Interestingly, expression of M protein of SARS-CoV can augment immune responses induced by NP protein of a SARS-CoV DNA vaccine [75].…”

Section: Potential Strategies For Developing Mers Vaccinesmentioning

confidence: 99%

Current advancements and potential strategies in the development of MERS-CoV vaccines

Zhang

Jiang

2014

Expert Review of Vaccines

161

View full text Add to dashboard Cite

Middle East respiratory syndrome (MERS) is a newly emerging infectious disease caused by a novel coronavirus, MERS-coronavirus (MERS-CoV), a new member in the lineage C of β-coronavirus (β-CoV). The increased human cases and high mortality rate of MERS-CoV infection make it essential to develop safe and effective vaccines. In this review, the current advancements and potential strategies in the development of MERS vaccines, particularly subunit vaccines based on MERS-CoV spike (S) protein and its receptor-binding domain (RBD), are discussed. How to improve the efficacy of subunit vaccines through novel adjuvant formulations and routes of administration as well as currently available animal models for evaluating the in vivo efficacy of MERS-CoV vaccines are also addressed. Overall, these strategies may have important implications for the development of effective and safe vaccines for MERS-CoV in the future.

show abstract

Immunization of Mice with a DNA Vaccine Based on Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fragment 1

Cited by 7 publications

References 20 publications

Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection

Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity

Current advancements and potential strategies in the development of MERS-CoV vaccines

Contact Info

Product

Resources

About